The currently available antipsychotics mostly treat the positive symptoms of schizophrenia
and have at least one adverse effect as a potential liability. Encouraging data suggest …

Experimental therapeutic research for schizophrenia is rapidly expanding and a number of
compounds with novel mechanisms of action are demonstrating encouraging evidence for …

Schizophrenia is a chronic and often severe mental disorder for which antipsychotic drugs
are the cornerstone of treatment. Although the essential mechanism of action of these drugs …

Schizophrenia remains one of the most severe medical diseases. Current dopamine
modulating first-generation and second-generation antipsychotics target mainly positive …

The introduction of the first antipsychotic medication in the early 1950s revolutionized mental
health care strategies and led to the era of deinstitutionalization, a period in which patients …

Following the introduction of the first antipsychotic agents in the early 1960s, the
pharmacotherapy of schizophrenia essentially stagnated for a long time. Many new …

Introduction: Despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a
large percentage of persons with schizophrenia remain at least partially nonresponsive to …

Introduction: Schizophrenia is one of the most serious mental disorders. Its treatment
remains challenging, as existing antipsychotic antidopaminergic medications improve …

The pharmacological choices for the treatment of schizophrenia have been greatly
expanded with the availability of the atypical compounds clozapine (Clozaril®, Novartis) …

Schizophrenia: Overview and Treatment Options - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …